Giovanni Mori

1 Introduction Invasive candidiasis (IC) and candidemia remain life-threatening infections, particularly in critically ill and immunocompromised patients. Successful management has been complicated by the shift of Candida albicans to non-albicans species over the past decade, including Candida glabrata (Nakaseomyces glabratus), Candida parapsilosis, and Candida auris [1]. Echinocandins remain the first-line antifungal for IC, whereby treatment requires daily intravenous (i.v.) administration [2].

Abstract Incidence of breakthrough proven-probable invasive fungal infections (b-PP-IFIs) in allogeneic haematopoietic cell transplant recipients (allo-HCT-r) receiving mould-active prophylaxis (MAP) and post-transplant cyclophosphamide (PT-Cy) is largely unknown.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.